Jubilant Pharmova Ltd - Company Profile
Powered by 
All the sales intelligence you need on Jubilant Pharmova Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Jubilant Pharmova Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Jubilant Pharmova Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Jubilant Pharmova Ltd (Jubilant) is an integrated pharmaceutical company. The company manufactures and supplies active pharmaceutical ingredients (APIs), solid dosage formulations, allergy therapy products, radiopharmaceuticals, and many more India-branded pharmaceuticals. Jubilant offers contract manufacturing services for sterile injectables and non-sterile products and drug discovery services. The company is also engaged in the fields of oncology and autoimmune diseases. The company provides its products and services to customers across the US, India, South Africa, Canada, Singapore, Belgium and China. It owns and operates cGMP-compliant manufacturing facilities and research and development centers in India, the US and Canada. Jubilant is headquartered in Noida, Uttar Pradesh, India.
Headquarters
India
Address
1A, Sector 16A, Noida, Uttar Pradesh, 201301
Website
www.jubl.com
Telephone
91 120 4361000
No of Employees
978
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
JUBLPHARMA (NSE)
Revenue (2024)
$864.7M
7.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
988.7%
(2024 vs 2023)
Market Cap*
$1.7B
Net Profit Margin (2024)
XYZ
908.7%
(2024 vs 2023)
* As of and is in US$
Jubilant Pharmova Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Generic Pharmaceuticals | Drug Discovery Solutions | Draximage |
| Active Pharmaceutical Ingredients | Contract Manufacturing Services | Ruby-Fill |
| Radiopharmaceuticals | Contract Research and Development Services | Hicon |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In October, Jubilant HollisterStier LLC introduced its New Sterile Fill & Finish line at its Spokane Manufacturing Facility in Washington, the US. |
| 2025 | Regulatory Approval | In September, the company completed the United States Food and Drug Administration Post-marketing Adverse Drug Experience inspection of Jubilant Cadista Pharmaceuticals Inc, USA. |
| 2024 | Contracts/Agreements | In November, Jubilant Radiopharma partnered with Simplified Imaging Solutions to improve the efficiency of nuclear medicine services for healthcare providers across the US. |
Competitor Comparison
| Key Parameters | Jubilant Pharmova Ltd | Teva Pharmaceutical Industries Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Divi's Laboratories Ltd |
|---|---|---|---|---|---|
| Headquarters | India | Israel | India | India | India |
| City | Noida | Tel Aviv | Mumbai | Hyderabad | Hyderabad |
| State/Province | Uttar Pradesh | Tel Aviv | Maharashtra | Telangana | Telangana |
| No. of Employees | 978 | 31,173 | 43,000 | 26,944 | 18,300 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shyam S. Bhartia | Chairman | Executive Board | 1978 | 72 |
| Shantanu Jha | Chief Human Resources Officer | Senior Management | 2023 | - |
| Hari S. Bhartia | Co-Chairman | Executive Board | - | 68 |
| Arjun Shanker Bhartia | Director; Joint Managing Director | Executive Board | 2017 | 36 |
| Priyavrat Bhartia | Director; Managing Director | Executive Board | 2023 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer